Evidence map›Paper›PMID 28288189›Full record

ArticlePLoS pathogens2017

Complete mapping of viral escape from neutralizing antibodies.

Michael B Doud, Scott E Hensley, Jesse D Bloom

Abstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Michael B DoudBasic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.ORCID 0000-0002-8172-6342
Scott E HensleyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Jesse D BloomBasic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.ORCID 0000-0003-1267-3408

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
Understanding Transmission with Integrated Genetic and Epidemiologic InferenceU54GM111274 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI VESPIGNANI, ALESSANDRO · 2014 to 2018
$12.5M
Impact of prior influenza exposures on antibody repertoires to new viral strainsR01AI108686 · NIAID · WISTAR INSTITUTE · PI HENSLEY, SCOTT ERIC · 2014 to 2022
$3.7M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
The effect of human pre-exposure history on antigenic drift of influenza virusesR01AI113047 · NIAID · WISTAR INSTITUTE · PI HENSLEY, SCOTT ERIC · 2014 to 2018
$2.5M
High-throughput experiments to guide influenza vaccine strain selectionR01AI127893 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2016 to 2020
$2.1M
Mapping epistasis in molecular evolution: the influenza nucleoproteinR01GM102198 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2012 to 2016
$1.6M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI108686NIAID NIH HHS R01 AI113047NIAID NIH HHS R01 AI127893NIAID NIH HHS T32 AI083203NIGMS NIH HHS R01 GM102198NIGMS NIH HHS T32 GM007266NIGMS NIH HHS U54 GM111274NIH HHS S10 OD020069
6 · The paper itself

Abstract

Identifying viral mutations that confer escape from antibodies is crucial for understanding the interplay between immunity and viral evolution. We describe a high-throughput approach to quantify the selection that monoclonal antibodies exert on all single amino-acid mutations to a viral protein. This approach, mutational antigenic profiling, involves creating all replication-competent protein variants of a virus, selecting with antibody, and using deep sequencing to identify enriched mutations. We use mutational antigenic profiling to comprehensively identify mutations that enable influenza virus to escape four monoclonal antibodies targeting hemagglutinin, and validate key findings with neutralization assays. We find remarkable mutation-level idiosyncrasy in antibody escape: for instance, at a single residue targeted by two antibodies, some mutations escape both antibodies while other mutations escape only one or the other. Because mutational antigenic profiling rapidly maps all mutations selected by an antibody, it is useful for elucidating immune specificities and interpreting the antigenic consequences of viral genetic variation.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralGenetic VariationHemagglutinin Glycoproteins, Influenza VirusHigh-Throughput Nucleotide SequencingImmune EvasionMutationNeutralization TestsOrthomyxoviridaeAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralHemagglutinin Glycoproteins, Influenza Virus

Identifiers

PMID28288189
PMCPMC5363992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.